Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 18/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19512842 | 0.88 | GRM5 (0.46) | GRM5KCNJ1KCNH2 | |
| SCHEMBL20945399 | 0.85 | KCNJ1 (0.57) | GRM5KCNJ1KCNH2 | |
| SCHEMBL30569153 | 0.85 | KCNJ1 (0.57) | GRM5KCNJ1KCNH2 | |
| SCHEMBL30569167 | 0.81 | KCNJ1 (0.65) | GRM5KCNJ1KCNH2 | |
| SCHEMBL20945421 | 0.81 | KCNJ1 (0.65) | GRM5KCNJ1KCNH2 | |
| SCHEMBL19513099 | 0.78 | KCNJ1 (0.58) | GRM5KCNJ1KCNH2 | |
| SCHEMBL30569165 | 0.78 | KCNJ1 (0.58) | GRM5KCNJ1KCNH2 | |
| SCHEMBL19513100 | 0.77 | KCNJ1 (0.77) | KCNJ1KCNH2 | |
| SCHEMBL30569178 | 0.77 | KCNJ1 (0.77) | KCNJ1KCNH2 | |
| SCHEMBL19475645 | 0.76 | GRM5 (0.43) | GRM5KCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | claimed |
| US-10851108-B2 | Substituted bicyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | claimed |
| US-20190127380-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-02 | — | — | US | claimed |
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | disclosed |
| US-10851108-B2 | Substituted bicyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190127380-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127380-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | NR0B1, GRK4, CRKL | GRM5 1609/4885KCNJ1 245/4885KCNH2 460/4885 |
| US-10851108-B2 | Substituted bicyclic heterocyclic compounds | NR0B1, GRK4, CRKL | GRM5 1609/4885KCNJ1 245/4885KCNH2 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.